News
The company said it planned to seek Food and Drug Administration approval for the drug, orforglipron, before the end of the ...
Eli Lilly raised its full-year profit forecast on Thursday, betting on surging demand for its blockbuster weight-loss drug, ...
In the first Phase 3 trial of its once-daily oral GLP-1 pill in people with obesity, drugmaker Eli Lilly said Thursday that ...
The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed ...
Eli Lilly's pill, orforglipron, is one step closer to becoming the first new, needle-free alternative in the booming market ...
In eagerly awaited results from a new study, the pharmaceutical company Eli Lilly reports that a pill its scientists ...
Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could ...
19h
Medpage Today on MSNWhen Is CPAP Associated With Cardiovascular Benefit ... vs Harm?
In a pooled analysis of three randomized trials, CPAP had overall null cardiovascular effects in patients with obstructive ...
Earnings, adjusted for one-time gains and costs, came to $6.31 per share. The results surpassed Wall Street expectations. The ...
As other pharmas drop next-gen obesity assets, Eli Lilly’s experimental oral GLP-1 has prompted weight loss up to an average ...
Eli Lilly has hoped its candidate weight loss pill would safeguard its lead in the obesity market, but new results may prove ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results